(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.47%) $27.23
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $7.33
発行日: 15 2月 2024 @ 03:17
リターン: 44.20%
前回のシグナル: 2月 14 - 23:30
前回のシグナル:
リターン: 6.23 %
Live Chart Being Loaded With Signals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases...
Stats | |
---|---|
本日の出来高 | 193 217 |
平均出来高 | 475 155 |
時価総額 | 273.83M |
EPS | $0 ( 2024-03-06 ) |
次の収益日 | ( $-1.080 ) 2024-05-08 |
Last Dividend | $0.0690 ( 2017-09-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.740 |
ATR14 | $0.0200 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-26 | Weiner David B. | Buy | 972 | Common Stock |
2024-02-26 | Weiner David B. | Buy | 972 | Common Stock |
2024-02-26 | Weiner David B. | Buy | 972 | Common Stock |
2024-02-26 | Weiner David B. | Sell | 972 | Restricted Stock Unit |
2024-02-26 | Weiner David B. | Sell | 972 | Restricted Stock Unit |
INSIDER POWER |
---|
61.43 |
Last 100 transactions |
Buy: 3 683 868 | Sell: 932 723 |
ボリューム 相関
Inovio Pharmaceuticals 相関
10 最も正の相関 | |
---|---|
AKTX | 0.966 |
LSXMA | 0.961 |
LSXMK | 0.961 |
STRO | 0.95 |
TUEM | 0.948 |
ASPU | 0.946 |
OPHC | 0.943 |
CMLS | 0.942 |
WATT | 0.942 |
AADI | 0.941 |
10 最も負の相関 | |
---|---|
CPTA | -0.952 |
SGEN | -0.946 |
RAM | -0.936 |
GPACU | -0.936 |
NVSA | -0.936 |
COCO | -0.934 |
MLAI | -0.932 |
PESI | -0.928 |
PTOC | -0.928 |
FRSG | -0.927 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Inovio Pharmaceuticals 相関 - 通貨/商品
Inovio Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $832 010 |
総利益: | $-2.67M (-321.09 %) |
EPS: | $-6.09 |
FY | 2023 |
収益: | $832 010 |
総利益: | $-2.67M (-321.09 %) |
EPS: | $-6.09 |
FY | 2022 |
収益: | $10.26M |
総利益: | $4.77M (46.44 %) |
EPS: | $-14.47 |
FY | 2021 |
収益: | $1.77M |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.450 |
Financial Reports:
No articles found.
Inovio Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0690 | 2017-06-28 |
Last Dividend | $0.0690 | 2017-09-28 |
Next Dividend | $0 | N/A |
Payout Date | 2017-10-16 | |
Next Payout Date | N/A | |
# dividends | 4 | -- |
Total Paid Out | $0.276 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.17 | -- |
Div. Sustainability Score | 2.18 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0.449 | -- |
Year | Amount | Yield |
---|---|---|
2017 | $0.276 | 3.90% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 3 430.55 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 16.50 | 1.200 | 10.00 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 18.29 | 1.500 | 10.00 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.60 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.47 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0.336 | 1.500 | 9.24 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.175 | -1.500 | 7.09 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -241.59 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -5.80 | 2.00 | -1.932 | -3.86 | [0 - 30] |
freeCashFlowPerShareTTM | -5.81 | 2.00 | -2.90 | -5.81 | [0 - 20] |
debtEquityRatioTTM | 0.257 | -1.500 | 8.97 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | -38.10 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -173.00 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -4.37 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.00481 | 0.800 | -3.30 | -2.64 | [0.5 - 2] |
Total Score | 2.18 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 0.0844 | 1.000 | -0.0925 | 0 | [1 - 100] |
returnOnEquityTTM | 18.29 | 2.50 | 10.00 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -5.81 | 2.00 | -1.936 | -5.81 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -5.80 | 2.00 | -1.932 | -3.86 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0000652 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -158.77 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -1.283 |
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。